Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Amvuttra™ (vutrisiran) – New orphan drug approval
June 13, 2022 - Alnylam announced the FDA approval of Amvuttra (vutrisiran), for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
